GH SecretagogueSubcutaneous

Tesamorelin

Also known as: Egrifta · TH9507

Stabilized GHRH(1-44) analog. FDA-approved for HIV-associated lipodystrophy. Reduces visceral adipose tissue specifically while elevating IGF-1, and shows cognitive benefits in mild cognitive impairment trials.

At a glance

Half-life: 24 minutes
Common route: Subcutaneous
Typical dose range: 1,000–2,000mcg
Stability (reconstituted): 7days refrigerated

Best timing

Once daily, ideally pre-bed on an empty stomach. Effect on visceral fat takes 12+ weeks.

Contraindications

Active cancer
Pituitary tumor or hypothalamic disease
Pregnancy
Severe insulin resistance

Watch symptoms

Joint pain (most common)
Mild peripheral edema
Hyperglycemia
Injection site reactions
Headache, paresthesias

Citations

The primary literature.

01Effects of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulationPubMed
02GHRH analog tesamorelin and cognition in older adults with mild cognitive impairmentPubMed

Related protocols

Stacks that use Tesamorelin.

Body Recomp Stack

Twelve-week tesamorelin + ipamorelin + BPC-157 protocol for lean recomposition.

View protocol

Back to library